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A B S T R A C TObjectives: The Mount Hood Challenge meetings provide a forum for
computer modelers of diabetes to discuss and compare models, to
assess predictions against data from clinical trials and other studies,
and to identify key future developments in the field. This article reports
the proceedings of the Fifth Mount Hood Challenge in 2010. Methods:
Eight modeling groups participated. Each group was given four model-
ing challenges to perform (in type 2 diabetes): to simulate a trial of a
lipid-lowering intervention (The Atorvastatin Study for Prevention of
Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes
Mellitus [ASPEN]), to simulate a trial of a blood glucose–lowering
intervention (Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation [ADVANCE]), to
simulate a trial of a blood pressure–lowering intervention (Cardiovas-
cular Risk in Diabetes [ACCORD]), and (optional) to simulate a second
trial of blood glucose–lowering therapy (ACCORD). Model outcomes for
each challenge were compared with the published findings of the
respective trials. Results: The results of the models varied from eachsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.002
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bart, TAS 7000, Australia.other and, in some cases, from the published trial data in important
ways. In general, the models performed well in terms of predicting the
relative benefit of interventions, but performed less well in terms of
quantifying the absolute risk of complications in patients with type 2
diabetes. Methodological challenges were highlighted including match-
ing trial end-point definitions, the importance of assumptions con-
cerning the progression of risk factors over time, and accurately
matching the patient characteristics from each trial. Conclusions: The
Fifth Mount Hood Challenge allowed modelers, through systematic
comparison and validation exercises, to identify important differences
between models, address key methodological challenges, and discuss
avenues of research to improve future diabetes models.
Keywords: computer simulation, cost-effectiveness analysis, diabetes,
health economics, modeling.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
A decade after Jonathan Brown and Andrew Palmer met to
compare the 20-year predictions of two computer simulation
models of type 2 diabetes in the Timberline Lodge, high on the
side of Mount Hood near Portland, Oregon, the fifth Mount Hood
Challenge meeting was held in Malmo¨, Sweden, in September
2010 [1]. A total of eight modeling groups participated in the 2010
challenge, which followed a similar format to previous Mount
Hood meetings whereby modelers were asked to use their
prediction models to simulate the outcomes of clinical studies
to inform debate on the challenges facing groups working in
this area.
Computer simulation models, in essence a series of mathe-
matical equations combined in a structured framework, have
many uses such as allowing data from clinical trials to be
extrapolated over longer time periods and to other populations.
By providing information for health care decision makers on
long-term clinical outcomes and costs, such models allow
informed choices to be made between available interventions.
As the issue of cost containment becomes ever more pertinentfor many health care decision makers, the reliance on computer
simulation modeling is increasing. This is particularly true of
chronic diseases such as type 2 diabetes, which develop over a
long period of time and are associated with significant morbidity
and mortality and a substantial economic burden [2].
Although cost-of-illness studies have taught us a great deal
about the scale of the economic burden associated with diabetes,
as well as the identity of the main cost drivers, they do little to
help us understand the incremental value of new interventions
in a given population. Clinical trials provide essential information
on new interventions, but their limitations in terms of time
frame (typically 1–3 years), tightly controlled designs, and often
(highly) selected populations can make their findings difficult to
generalize to other care settings or populations. Key parameters
such as demographics, life expectancy, patient management/
medical technology, treatment costs, and health budgets can
vary widely between regions and between countries. Flexible
computer models have the potential to overcome these problems
and provide valuable information, such as assessments of long-
term cost-effectiveness, for policymakers and reimbursement
decision makers. To fulfill this role, models must be based onSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
stitute Tasmania, Medical Science 1 Building, 17 Liverpool Street
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(internal and external validation) as well as each other, and they
must also be transparent, documented in detail, and open about
their mechanisms and assumptions.
The aim of this article was to report the proceedings of the
Fifth Mount Hood Challenge held in Malmo¨, Sweden, in 2010,
with a view to providing a summary of how eight current
diabetes models match up to data from published clinical studies
as well as to each other, to highlight differences between models,
and to offer an insight into the challenges facing diabetes models
a decade after the First Mount Hood Challenge.Research Design and Methods
The Fifth Mount Hood Challenge was the first meeting for 6 years
(since the Fourth Mount Hood Challenge in 2004 [3]), and
participating modelers were asked to perform simulations based
on four published clinical trial data sets, thereby allowing
comparison of all eight participating models against clinical data.
Treatments and interventions, management of patients, and
cohort characteristics were defined in advance to minimize the
number of potentially disparate assumptions required to make
reliable forecasts over the duration of follow-up reported in the
trial publications. The working hypothesis for the Mount Hood
Challenge was that this process of standardized comparison is
the best method to identify differences between models as well
as assess the models’ reliability in predicting the consequences
of changes in risk factors brought about by an intervention in a
clinical trial situation. Readers are referred to the Mount Hood
web site for details of instructions given to modeling groups, and
for contact details of modeling groups for further clarifications or
detailed information regarding individual model structures and
assumptions [4]. All groups with a published simulation model of
type 2 diabetes were invited to take part in the challenge. In total,
eight groups accepted this year’s challenge. They were joined at
the meeting by 85 participants from 10 countries.Simulation Challenges in Type 2 Diabetes
To expand on the validation exercises from the Fourth Mount
Hood Challenge Meeting in 2004, the modelers performed four
external validation analyses against three recent clinical trials
that reported the results of interventions attempting to modify
key risk factors for the complications of type 2 diabetes. For each
of these trials, the modeling groups attempted to predict the
event rates of the primary end points and of as many secondary
outcomes as possible at the end of the study by using only the
size of the risk factor change achieved where possible within the
individual models’ frameworks, or using relative effects of treat-
ments if this was the only option with a model. All modeling
groups were restricted from using any information that they may
have had access to (e.g., patient-level data) that was not in the
public domain to produce the primary results set for presentation
at the meeting. Such data, however, could be used to produce an
additional set of results to examine whether model performance
could be improved. The end points reported (by default) by the
models did not always identically match those reported in the
clinical trials. While modeling groups were asked to report as
many outcomes as they could for each trial, some models could
not generate results for every end point. As a result, the results
tables are incomplete, with empty cells where no appropriate end
point for comparison was available from that model. Notable
differences in end-point definitions have been cited where
relevant in this article. Results were to be reported as the
proportion of patients experiencing each type of event (so as tomatch the outcomes reported in the trial publications). The
following challenges were set.Lipid-lowering intervention based on the Atorvastatin Study for
Prevention of Coronary Heart Disease Endpoints in Non-Insulin-
Dependent Diabetes Mellitus trial [5]
The Atorvastatin Study for Prevention of Coronary Heart Disease
Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
was a 4-year, double-blind, parallel group trial of 10 mg of
atorvastatin versus placebo in patients with type 2 diabetes and
low-density lipoprotein cholesterol levels below contemporary
guideline targets (r160 mg/dl [4.1 mmol/l], or r140 mg/dl [3.6
mmol/l] for subjects with myocardial infarction [MI] or coronary
intervention 43 months before screening). The composite pri-
mary end point comprised cardiovascular death, nonfatal MI,
nonfatal stroke, recanalization, coronary artery bypass surgery,
resuscitated cardiac arrest, and worsening or unstable angina
requiring hospitalization. Exclusion criteria included hemoglobin
A1c (Hb A1c) value of over 10% (86 mmol/mol), blood pressure over
160/100 mm Hg, body mass index (BMI) over 35 kg/m2, preexist-
ing liver disease, kidney disease, or heart failure treated with
digoxin. Patients were advised to adopt a National Cholesterol
Education Program diet (which is low in saturated and trans fats,
and rich in fruits, vegetables, whole grains, fat-free and low-fat
dairy products, and lean meat, fish, and poultry). A total of 2410
patients were randomly allocated to receive atorvastatin or
placebo. Mean patient age was 60 years, and approximately
two-thirds of the study population was male (Table 1). At the
end of the study, composite primary end point rates for atorvas-
tatin and placebo were 13.7% and 15.0%, respectively (hazard
ratio 0.90; 95% confidence interval [CI] 0.73–1.12). Subgroup
analysis in patients with a history of MI or interventional
procedure showed a hazard ratio of 0.82 (95% CI 0.59 –1.15). In
patients with no prior MI or interventional procedure, the hazard
ratio was estimated to be 0.97 (95% CI 0.74–1.28) for atorvastatin
versus placebo.Blood glucose–lowering intervention from the Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modified Release
Controlled Evaluation trial [6]
In the Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation (ADVANCE)
trial, a total of 11,140 patients with type 2 diabetes were
randomly assigned to undergo either standard glucose control
or intensive glucose control, defined as the use of gliclazide
(30–120 mg modified release) plus other drugs (metformin,
thiazolidinediones, acarbose, and/or insulin) as required to
achieve an Hb A1c value of 6.5% or less (Table 1). Primary end
points were composites of major macrovascular events (death
from cardiovascular causes, nonfatal MI, or nonfatal stroke) and
major microvascular events (new or worsening nephropathy or
retinopathy), assessed both jointly and separately. Inclusion
criteria included a history of macro- and microvascular disease
and age 55 years or more. Exclusion criteria included a require-
ment for insulin at the time of study initiation. After a median 5
years of follow-up, mean Hb A1c value was lower in the intensive-
control group (6.5%) than in the standard-control group (7.3%).
Intensive control reduced the incidence of combined major
macrovascular and microvascular events (18.1%, vs. 20.0% with
standard control; hazard ratio 0.90; P ¼ 0.01), as well as that of
major microvascular events (9.4% vs. 10.9%; P ¼ 0.01), primarily
because of a reduction in the incidence of nephropathy. The
hazard ratio for macrovascular events was 0.94 for intensive
treatment versus standard care (P ¼ 0.32, not significant).
Table 1 – Summary of population characteristics in the four challenges.
Characteristic ASPEN ADVANCE ACCORD BP ACCORD BG
Number of patients 2,410 11,140 4,733 10,251
Mean age (y) 60.0 66.3 63.2 62.2
Percentage males (%) 66 57 53 39
Percentage current smokers (%) 12 15 13 14
Mean body mass index (kg/m2) 29.0 27.0 32.2 32.2
Mean Hb A1c value (%) 8.0 8.0 8.0 8.0
Mean fasting plasma glucose (mmol/l) – 8.5 8.4 9.74
Median duration of diabetes (y) 8.0 8.2 9.8 10.0
Mean systolic blood pressure (mm Hg) 133.0 145.4 147.0 131.0
Mean diastolic blood pressure (mm Hg) 76.0 80.7 80.4 74.8
Mean LDL-cholesterol (mmol/l) 2.94 3.11 2.85 2.69
Mean HDL-cholesterol (mmol/l) 1.22 1.20 – –
Mean HDL-cholesterol (mmol/l) female/male –/– –/– 1.33/1.08 1.22/1.00
History of cardiovascular disease (%) – – 32 30
History of myocardial infarction (%) 17 12 – –
History of cerebrovascular disease or stroke 5 9 – –
ACCORD, Action to Control Cardiovascular Risk in Diabetes trial; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation; ASPEN, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-
Dependent Diabetes Mellitus; BP, blood pressure; BG, blood glucose; Hb A1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density
lipoprotein.
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Risk in Diabetes trial [7]: The Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial was designed to
investigate whether therapy targeting normal systolic blood pres-
sure (SBP) reduces major cardiovascular events in participants with
type 2 diabetes at high risk for cardiovascular events. A total of 4733
participants with type 2 diabetes were randomly assigned to
intensive therapy (target SBPo120 mm Hg) or standard therapy
(target SBPo140 mm Hg). The primary composite end point was
nonfatal MI, nonfatal stroke, or death from cardiovascular causes.
Mean follow-up was 4.7 years. Inclusion criteria included age 40
years or more, atherosclerosis, left ventricular hypertrophy, or two
or more risk factors from a list of serum lipid levels, smoking,
hypertension, and obesity. Patients were excluded if they had an Hb
A1c value below 7.5% (58mmol/mol) or BMI above 45 kg/m
2. Baseline
cohort characteristics are summarized in Table 1. The annual rate of
the primary outcome was 1.87% in the intensive-therapy group and
2.09% in the standard-therapy group (hazard ratio 0.88; P ¼ 0.20, not
significant). The annual rates of death from any cause were 1.28%
and 1.19% in the two groups, respectively (P ¼ 0.55, not significant),
but the annual rates of stroke, a prespecified secondary outcome,
were significantly different (0.32% vs. 0.53%, P ¼ 0.01).
Blood glucose–lowering intervention from the ACCORD trial [8]
The ACCORD trial also examined the efficacy of intensive glucose
lowering–therapy on mortality and key cardiovascular events in
patients with advanced type 2 diabetes and a high risk of
cardiovascular events. In the glucose-lowering study, 10,251
patients with a median Hb A1c value of 8.1% were assigned to
receive intensive therapy (target Hb A1c value below 6.0%) or
standard therapy (targeting an Hb A1c value of 7.0%–7.9%). Of
these patients, 38% were women and 35% had had a previous
cardiovascular event (Table 1). The primary outcome was a
composite of nonfatal MI, nonfatal stroke, or death from cardi-
ovascular causes (i.e., the same composite as used in the blood
pressure study). Because of a higher mortality rate in the
intensive-therapy group, intensive therapy was discontinued after
a mean of 3.5 years of follow-up. At the end of follow-up, the
primary outcome occurred in 352 patients (6.9%) in the intensive-
therapy group, versus 371 (7.2%) in the standard-therapy group(hazard ratio 0.90; P ¼ 0.16, nonsignificant). Two hundred fifty-
seven patients (5%) in the intensive-therapy group died, however,
compared with 203 patients (4%) in the standard-therapy group
(hazard ratio 1.22; P ¼ 0.04).
Overview of Models Participating in the Fifth Mount Hood
Challenge
Eight models were represented at the meeting (in order of
presentation): the IMS CORE Diabetes Model, the University of
Michigan Model for Diabetes (Michigan Model), The Swedish
Institute of Health Economics model entitled the Economics
and Health Outcomes in Type 2 Diabetes Mellitus (ECHO-T2DM)
Model, the United Kingdom Prospective Diabetes Study (UKPDS)
Outcomes Model, The UKPDS Risk Engine, the Centers for Disease
Control (CDC)-RTI Diabetes Cost-effectiveness Model, the Cardiff
Research Consortium Model (Cardiff Model), and the Evidence-
Based Medicine Integrator (EBMI) Simulator. The models pre-
sented results on all four validation challenges based on the
outcomes reported by each respective model. The EBMI Simulator
did not report results on the ASPEN challenge. Each presenting
model team prepared a brief model description, which is pro-
vided in the following paragraphs (in order of presentation).
IMS CORE Diabetes Model [9,10]
The IMS CORE Diabetes Model is a non–product-specific, diabetes
policy analysis tool that performs real-time simulations. Disease
progression is based on a series of interdependent Markov
submodels that simulate diabetes-related complications (angina,
MI, congestive heart failure, stroke, peripheral vascular disease,
diabetic retinopathy, macular edema, cataract, hypoglycemia,
ketoacidosis, nephropathy and end-stage renal disease, neuro-
pathy, foot ulcer, and amputation). Each submodel uses time-,
state- and diabetes-type–dependent probabilities derived from
published sources, and utilizes tracker variables to overcome the
memoryless properties of standard Markov models. The progres-
sion of relevant physiological parameters (e.g., Hb A1c, SBP, lipids,
and BMI) is simulated on the basis of long-term epidemiological
data, and event risk is constantly updated on the basis of these
risk factors. Analyses, including first- and second-order Monte
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either type 1 or type 2 diabetes, defined in terms of age, gender,
baseline risk factors, preexisting complications, and comorbid-
ities. The model is adaptable, allowing the inclusion of new
clinical and economic data as these become available. The
creation of country-, health maintenance organization-, or
provider-specific versions of the model is possible. The reliability
of simulated clinical outcomes has been tested, with results
validated against those reported from clinical trials and epide-
miological studies.
The Michigan Model [11,12]
The Michigan Model for Diabetes has been substantially revised
since its original publication in 2005 and is implemented by using
newly developed software that models chronic diseases. This
software provides an environment for model design, estimation,
and simulation, as well as a convenient graphical user interface
to 1) define parameters, 2) define populations, 3) generate
populations from distributions, 4) create a new disease model
or modify an existing model, 5) simulate the behavior of a given
base population by using a defined model enhanced by a set of
simulation rules, and 6) analyze and report simulation results.
These capabilities support models expressed as multiple nested
extended Markov subprocesses. It uses Monte Carlo simulation to
simulate disease progression. As a result, the software system is
very general and can accommodate many chronic disease mod-
els in the same software environment, which enables it to
compare and contrast results from alternative models.
The current version of the software simulates disease pro-
gression in the following disease processes: diabetes, nephrop-
athy, neuropathy, retinopathy, cardiovascular disease (CVD), and
cerebrovascular disease. It calculates costs and utility scores for
user-specified time periods. Users can specify the frequency of
examination (which results in diagnosis) and the rate of com-
pliance with treatment (which affects the rate of disease pro-
gression) among other things. The Michigan Model for Diabetes is
publicly available under a General Public License and can be
downloaded from the Michigan Diabetes Research and Training
Center web site (www.med.umich.edu/mdrtc/cores/DiseaseModel/
index.html).
ECHO-T2DM [13]
ECHO-T2DM is a (second-order) stochastic, microsimulation
model that consists of Markov health states representing the
development and consequences of key micro- and macrovascular
complications. A cohort of hypothetical type 2 diabetes patients
is generated from a probability distribution of initial patient
characteristics (both demographic and health-related). Hb A1c is
the core driver of the model, affecting both outcomes and
changes in treatment. Patients are initially treated with one of
two user-specified treatment paradigms, and their evolving
health and treatment needs are simulated annually until the
end of the user-defined time horizon or death (if occurring
sooner). Patient health is recorded by using health states that
capture the existence and severity of retinopathy, nephropathy,
neuropathy, and CVD (as defined in the UKPDS) and is updated on
an annual basis.
Diabetes treatment is governed by an algorithm that seeks to
maintain user-defined Hb A1c treatment thresholds. User-defined
inputs control the algorithm (making it flexible). Treatment
affects Hb A1c but can also affect BMI, SBP, and lipid levels, and
can be initiated or discontinued and new agents added to meet
Hb A1c goals. Treatments can also cause adverse events, includ-
ing hypoglycemia, which can lead to discontinuation or non-
compliance. The model estimates costs on the basis of the
treatment of diabetes-related complications and the costs ofblood glucose control. Utility scores are calculated by using
decrements for each complication. Model outcomes include
incidence rates for each of the complications and adverse events
modeled, incremental cost-effectiveness ratios, net monetary
benefit results, and acceptability curves.
UKPDS Outcomes Model [14]
The UKPDS Outcomes Model is a widely used simulation model
for type 2 diabetes based on patient-level data from the UKPDS. It
models the occurrence of seven diabetes-related end points (MI,
angina, stroke, heart failure, amputation, renal failure, and blind-
ness in one eye) and death to estimate quality-adjusted life
expectancy, life expectancy, and costs. In brief, the UKPDS Out-
comes Model is based on an integrated system of parametric
equations that predict the annual probability of any of the above
end points and Monte Carlo methods to predict the occurrence of
events. The likelihood of the end points is based on patient
demographics, duration of diabetes, risk factor levels, and history
of diabetes-related complications. Different treatment and man-
agement strategies are evaluated through their impact on risk
factor levels. A key aspect of the model is its ability to capture the
clustering or interaction of different types of complications at the
individual patient level. The model is a probabilistic discrete-time
illness-death model, rather than a Markov model. Patients start
with a given health status (e.g., age, sex, duration of diabetes, risk
factor values, and no complications) and can have one or more
nonfatal complications and/or die in any model cycle by compar-
ing estimated probabilities with random numbers drawn from a
uniform distribution ranging from 0 to 1 to determine whether an
event occurs. When a patient experiences a complication, their
utility is permanently decremented such that they accumulate
quality-adjusted life-years at a slower rate. Utility decrements
and costs associated with events are estimated from the same
patient-level data set. Elements of the UKPDS Outcomes Model
have been widely used in many other diabetes simulation
models. A software implementation of the model is available
under license from the University of Oxford (http://www.dtu.ox.
ac.uk/Outcomesmodel).
UKPDS Risk Engine [15–17]
The UKPDS Risk Engine is a type 2 diabetes–specific risk calcu-
lator based on over 50,000 patient-years of data collected
between 1977 and 2007. It is designed to provide estimates and
95% CIs for CVD risk in individuals with type 2 diabetes not
known to have heart disease. Risk estimates can be calculated for
any given duration of diabetes on the basis of current age, sex,
ethnicity, smoking status, presence or absence of atrial fibrilla-
tion, presence or absence of microalbuminuria or worse, and
levels of Hb A1c, SBP, total cholesterol, and high-density lip-
oprotein cholesterol.
The CDC-RTI Diabetes Cost-effectiveness Model [18–20]
The CDC-RTI Diabetes Cost-effectiveness Model is a Markov
simulation model of disease progression and cost-effectiveness
for type 2 diabetes that follows patients from diagnosis to either
death or an age of 95 years. The model simulates the develop-
ment of diabetes-related complications on three microvascular
disease pathways (nephropathy, neuropathy, and retinopathy)
and two macrovascular disease paths (coronary heart disease
and stroke). In the model, progression between disease states is
governed by transition probabilities that depend on risk factors
and duration of diabetes. Interventions affect the transition
probabilities and resulting complications. Model outcomes
include disease complications, deaths, costs, and quality-
adjusted life-years. A detailed description of the model and its
validation analysis can be found online [17,18].
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The Cardiff cost-utility model estimates the long-term economics
and health impact of managing patients with type 2 diabetes. The
core model is coded in Cþþ and linked to a Microsoft Excel front
end. The model is a fixed time increment (yearly) stochastic
simulation with a 40-year time horizon. The model utilizes the
UKPDS Outcomes Model equations (UKPDS 68 [12]) to predict
macrovascular and microvascular complications. The dynamic
profile of modifiable risk factors is controlled via user-
controllable equations, which also includes dynamic changes to
weight. The model is designed to evaluate a treatment and
control pathway, each of which is composed of up to three lines
of therapy. Therapy escalation is controlled via user-defined Hb
A1c thresholds.
The model incorporates the risk of hypoglycemia, which is
captured by using annual rates for the occurrence of sympto-
matic and nocturnal hypoglycemic events; these events are
associated with immediate cost and utility consequences. The
model is capable of running with mean values, with probabilistic
inputs and user-defined data with outputs for cost per life-year
gained and cost per quality-adjusted life-year gained, in addition
to the number, cost, and utility consequence of all events
occurring within the model.
Evidence-Based Medicine Integrator Simulator [24]
EBMI is a free, open-source medical computational framework
that integrates three kinds of knowledge by using stochastic
discrete-event microsimulation: risk estimates derived from
patient data, comparative effectiveness estimates obtained from
randomized clinical trials, and genetic knowledge from basic
research. EBMI is designed to be used with electronic medical
records to identify all potential treatments for every patient and
to recommend next treatment steps. It can also generate or
accept population data to do management, trial planning, policy,
and research studies. EBMI’s direct use of local data and clinical
trial results maximizes clinical safety. Assumptions are readily
changeable as new trials appear. The EBMI code and documenta-
tion are available at http://code.google.com/p/ebmi.
Currently, EBMI simulates all major macrovascular and micro-
vascular complications of type 2 diabetes, plus associated expen-
ditures and utility effects. Highly detailed protocols use natural
dosage increments for all classes of diabetes and CVD treat-
ments, plus user-defined classes. Event drive protocols are also
programmable. EBMI is designed to safely integrate reliable
knowledge with local circumstances, not to predict the results
of treatments that have not been trialed (although the user can
hypothesize effects). Therefore, the traditional hypothesis that
simulators should not be validated against trials does not apply
to EBMI in the usual way. It is important to demonstrate that
EBMI can reproduce the relative effects of treatment trials and
also reproduce local data where it is to be used. The EBMI version
used in the Fifth Mount Hood Challenge is derived from, and has
been validated against, the Kaiser Permanente Northwest diabe-
tes registry.Results
Model Predictions Based on the ASPEN Clinical Trial (Lipid-
Lowering Intervention)
The first of the validations at the Fifth Mount Hood Challenge
challenged the diabetes modelers to reproduce the findings of a
lipid-lowering therapy from the ASPEN clinical trial in patients
with elevated low-density lipoprotein levels. Comparison with
the primary composite end point from ASPEN (cardiovasculardeath, nonfatal MI, nonfatal stroke, recanalization, coronary
artery bypass surgery, resuscitated cardiac arrest, and worsening
or unstable angina requiring hospitalization) showed that the
four models reporting a value underestimated the overall risk in
both the atorvastatin and placebo treatment groups (Table 2;
Figure 1). Interestingly, the models tended to overestimate the
risk of cardiovascular mortality and MI events (except the Cardiff
Model, which underestimated the incidence of these events), but
underestimated the risk of stroke and notably overestimated the
risk of noncardiovascular mortality. This latter observation may
suggest that the data on mortality from other causes used in the
models do not reflect the standard of care that patients in the
ASPEN trial were receiving. Other interesting observations were
that some model appeared to perform better for primary versus
secondary cohorts (e.g., ECHO and CDC) and that, despite being
built using different approaches, the ECHO and CDC models
generated comparable results.
In terms of the relative risk of events on atorvastatin versus
placebo, which would be important in estimating absolute
benefits in a cost-effectiveness analysis where incremental val-
ues are reported, the models tended to overestimate the benefit
of atorvastatin on the primary end point (Table 2). This was also
true of primary cardiovascular events and cardiovascular mortal-
ity, although the UKPDS Outcomes Model was an exception in
that it reported a relative risk of cardiovascular mortality closely
matching that in the ASPEN study. There were no obvious
modeling trends in terms of the relative risk of other end points
in the ASPEN study from the data presented.
Model Predictions Based on the ADVANCE Clinical Trial
(Glucose-Lowering Intervention)
In general, the results produced by the models in the validation
against the ADVANCE trial showed a reasonably close match with
reported trial results after 5 years of follow-up (Tables 3 and 4;
Figures 2 and 3). Models tended to overestimate the incidence of
major macrovascular events, with the UKPDS Outcomes Model,
the EBMI Simulator, and the IMS CORE Diabetes Model offering
the closest estimates to the trial data. Models also tended to
overestimate the risk of coronary events (major and all) in both
the intensive and standard glucose control treatment groups in
the ADVANCE trial. In terms of specific macrovascular events, the
models overestimated MI risk, underestimated stroke and heart
failure risk, and overestimated CVD mortality. Model estimations
of overall mortality (death from any cause) were, as in the
validation against the ASPEN study, underestimated by two of
the three models reporting this end point.
Estimates of the incidence of microvascular complications
showed that models generally underestimated the overall risk of
nephropathy and retinopathy as defined in the ADVANCE trial.
Similarly, the models reporting values tended to underestimate
the risk of new-onset microalbuminuria and new or worsening
neuropathy in comparison with the trial data. (This latter end
point was challenging for several of the models.)
In terms of the relative risk of complications between the
intensive and standard glucose control treatment arms in the
ADVANCE trial, the models performed reasonably well in esti-
mating the relative risk of major macrovascular events, major
coronary events, nonfatal MI, and heart failure (Tables 3 and 4). In
general, the models overestimated the benefit of intensive glu-
cose control on stroke risk and very slightly underestimated the
benefit on cardiovascular mortality. In contrast, there was a
tendency to underestimate the benefit of intensive glucose
control on all-cause mortality. None of the models closely
predicted the occurrence of more major cerebrovascular events
in the intensive glucose control group of the ADVANCE trial
relative to the standard-control group. Overall, the relative risk
Table 2 – Summary of validation results for a lipid-lowering intervention in the ASPEN trial.
Model Primary
composite
end point
CVD
mortality
(Prim/Sec)
Non-CVD
mortality
(Prim/Sec)
Fatal/nonfatal
MI (Prim/Sec)
Fatal/
nonfatal
stroke
Angina Primary
event
Secondary
event
ASPEN
Control 15.0% 3.1% (2.5/5.6) 2.6% (2.3/3.6) 5.5% (3.6/12.6) 3.1% 3.2% 10.8% 30.8%
Intervention 13.7% 3.1% (2.0/7.1) 2.6% (2.1/4.8) 4.0% (2.9/8.3) 3.0% 2.8% 10.4% 26.2%
IMS CORE
Control 3.9% (2.2/10.7) 5.7% (5.1/8.5) 5.8% (4.8/11.4) 2.5%
Intervention 3.4% (1.8/10.3) 5.5% (4.9/8.4) 4.5% (3.6/9.1) 2.0%
MICHIGAN
Control 3.3% 2.3% (2.5/–) 3.9% (3.2/–) 3.4% 2.7%
Intervention 2.7% 2.8% (2.5/–) 6.1% (5.5/–) 3.0% 2.1%
ECHO-T2DM
Control 14.8% 5.0% (4.0/8.0) 5.1% (4.0/11.2) 8.5% (7.1/14.9) 12.7% 23.9%
Intervention 12.3% 4.3% (3.3/7.4) 4.9% (3.9/10.3) 6.7% (5.6/11.9) 10.5% 20.4%
UKPDS OM
Control 11.1% 4.1% 7.4% 6.1% 2.8% 1.9%
Intervention 9.6% 4.1% 7.0% 5.2% 2.5% 2.3%
UKPDS RE
Control 8.7%
Intervention 7.4%
CDC-RTI
Control 14.3% 5.5% (3.3/13.9) 6.4% (6.3/6.6) 9.4% (8.0/14.4) 12.2% 22.4%
Intervention 12.4% 5.0% (2.8/13.7) 6.4% (6.4/6.6) 8.1% (6.4/14.4) 10.0% 21.5%
CARDIFF
Control (1.7/3.1) (4.1/6.0) (3.1/5.8)
Intervention (1.5/3.5) (4.1/6.0) (2.7/5.8)
ASPEN 2006 Relative risk 0.91 1.00 1.00 0.73 0.97 0.88 0.96 0.85
IMS CORE Relative risk 0.88 0.97 0.77 0.77
MICHIGAN 0.81 0.64 0.79
ECHO-T2DM 0.83 0.87 0.96 0.79 0.82 0.85
UKPDS OM 0.86 1.00 0.95 0.85 0.91 0.84
UKPDS RE 0.84
CDC-RTI 0.87 0.91 1 0.86 0.82 0.96
CARDIFF
Notes. Relative risk represents the ratio of event risk in the intervention group versus the control group. Results were reported in the trials and by some of the modeling groups for all patients,
primary prevention patients, and secondary prevention patients. Results in parentheses are for the primary/secondary prevention subgroups, respectively.ASPEN, Atorvastatin Study for
Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus, a 4-year, double-blind, parallel group trial of 10 mg of atorvastatin versus placebo in patients with
type 2 diabetes and LDL-cholesterol levels below contemporary guideline targets; CARDIFF, Cardiff Research Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-RTI
Diabetes Cost-effectiveness Model; CVD, cardiovascular disease; ECHO-T2DM, The Swedish Institute of Health Economics model titled Economics and Health Outcomes in Type 2 Diabetes
Mellitus Model; IMS CORE, IMS CORE Diabetes Model; LDL, low-density cholesterol; MI, myocardial infarction; MICHIGAN, The Michigan Model for Diabetes; Prim, primary prevention group;
Sec, secondary prevention group; UKPDS OM, the United Kingdom Prospective Diabetes Study Outcomes Model; UKPDS RE, the United Kingdom Prospective Diabetes Study Risk Engine.
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Fig. 1 – Summary of model validation results for the ASPEN trial. ASPEN, Atorvastatin Study for Prevention of Coronary Heart
Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus, a 4-year, double-blind, parallel group trial of 10 mg of
atorvastatin versus placebo in patients with type 2 diabetes and LDL-cholesterol levels below contemporary guideline
targets; CARDIFF, Cardiff Research Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-RTI Diabetes
Cost-effectiveness Model; CVD, cardiovascular disease; ECHO-T2DM, The Swedish Institute of Health Economics model titled
Economics and Health Outcomes in Type 2 Diabetes Mellitus Model; IMS CORE, IMS CORE Diabetes Model; LDL, low-density
lipoprotein; MI, myocardial infarction; MICHIGAN, The Michigan Model for Diabetes; Prim, primary; Sec, secondary; UKPDS
OM, the United Kingdom Prospective Diabetes Study Outcomes Model; UKPDS RE, the United Kingdom Prospective Diabetes
Study Risk Engine.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 7 0 – 6 8 5676of microvascular complications was generally in line with the
observations made in the trial, but there was a notable spread of
relative risk values for nephropathy and retinopathy between
models. The Michigan Model produced some outliers in the
validation against the ADVANCE data because of differing end-
point definitions for microvascular complications between the
trial and the modeling analysis.
Model Predictions Based on the ACCORD Clinical Trial (Blood
Pressure–Lowering Intervention)
In the validation focused on a blood pressure–lowering interven-
tion in the ACCORD trial, the models generally performed well in
terms of reproducing the primary end point (nonfatal MI, non-
fatal stroke, or death from cardiovascular causes) over 4.7 years
of follow-up (Table 5; Figure 4). Most models produced values
comparable to the trial data set for the end points of stroke (any)
and nonfatal MI, although the IMS CORE Diabetes Model and the
Cardiff Model underestimated the risk of MI in both the inter-
vention and control treatment groups. The models, in general,
provided overestimates of the risk of all-cause mortality with the
exception of the Cardiff Model, which closely matched the trial
data. Four models overestimated cardiovascular mortality (the
Michigan Model, the ECHO-T2DM Model, the CDC/RTI Model, and
the UKPDS Outcomes Model), and two models provided values
comparable with the ACCORD data (the IMS CORE Diabetes Model
and the Cardiff Model). The IMS CORE Diabetes Model, the ECHO-
T2DM Model, and the UKPDS Outcomes Model provided esti-
mates of heart failure risk in line with those observed in the trial,
whereas the Cardiff Model and the EBMI Simulator underesti-
mated and overestimated these risks, respectively.
In terms of relative risk, the models performed reasonably
well on the primary end point, major coronary events andnonfatal MI, but underestimated the benefit of the blood
pressure–lowering intervention on stroke risk (Table 5). For all-
cause mortality, none of the models predicted a higher mortality
rate in the intervention arm (aggressive blood pressure control)
than in the control arm as observed in the trial. Similarly, most
models failed to predict a similar trend in cardiovascular mortal-
ity in trial data, with the exceptions of the UKPDS Outcomes
Model and the Cardiff Model.
Model Predictions Based on the ACCORD Clinical Trial
(Glucose-Lowering Intervention)
Validation against the ACCORD blood glucose intervention trial
was an exploratory and optional analysis at the Fifth Mount Hood
Challenge Meeting (Table 6; Figure 5). The ACCORD study showed
that the use of intensive therapy to target normal Hb A1c levels
for 3.5 years increased mortality and did not significantly reduce
major cardiovascular events, a risk not previously identified in
clinical trials in type 2 diabetes [8]. Only the UKPDS Outcomes
Model and the ECHO-T2DM Model reported validation results for
the primary end point in the ACCORD trial (nonfatal MI, nonfatal
stroke, or death from cardiovascular causes; Table 6). The UKPDS
Outcomes Model provided estimates close to those reported in
the trial and the ECHO-T2DM Model slightly overestimated risk in
both the intensive glucose therapy arm and in the control arm.
Both models overestimated the benefit of intensive therapy
versus control on the primary end point. On the incidence of
nonfatal MI, the models offered a range of values that spanned
those reported in the trial, with the EBMI Simulator reporting
values closest to the ACCORD published data. In general, esti-
mates of nonfatal stroke incidence were comparable with those
reported in the ACCORD trial, but all models failed to predict the
increased risk of stroke observed in the intensive-treatment arm
Table 3 – Summary of validation results for a glucose-lowering intervention in the ADVANCE trial (primary end point).
Model CVD
mortality
All major
macrovascular/
microvascular
events
Major
macrovascular
events
Nonfatal
MI
Nonfatal
stroke
Major
microvascular
events
Nephropathy Retinopathy
ADVANCE
Intensive 4.5% 18.1% 10.0% 2.7% 3.8% 9.4% 4.1% 6.0%
Standard 5.2% 20.0% 10.6% 2.8% 3.8% 10.9% 5.2% 6.3%
IMS CORE
Intensive 4.2% 15.7% 11.3% 4.6% 2.6% 4.4% 2.3% 2.1%
Standard 4.6% 17.5% 12.2% 4.9% 2.7% 5.4% 2.8% 2.6%
MICHIGAN
Intensive 5.6% 56.1% 16.4% 7.4% 4.7% 46.6% 26.3% 27.8%
Standard 5.7% 55.9% 16.7% 7.7% 4.7% 46.0% 25.8% 27.4%
ECHO-T2DM
Intensive 6.6% 24.1% 16.1% 7.2% 3.0% 2.7% 6.9%
Standard 7.5% 30.1% 18.0% 7.9% 3.5% 4.3% 10.8%
UKPDS OM
Intensive 6.4% 10.5%
Standard 6.5% 11.4%
UKPDS RE
Intensive 13.1%
Standard 14.5%
CDC-RTI
Intensive 11.0% 26.0% 17.8% 8.2% 2.4% 5.8%
Standard 11.4% 29.5% 19.2% 10.3% 3.2% 7.1%
CARDIFF
Intensive 2.2% 2.2% 1.6%
Standard 2.4% 2.1% 1.6%
EBMI
Intensive 11.2% 21%
Standard 12.0% 21%
ADVANCE Relative risk 0.87 0.91 0.94 0.96 1.00 0.86 0.79 0.95
IMS CORE Relative risk 0.92 0.90 0.93 0.94 0.93 0.82 0.82 0.81
MICHIGAN 0.98 1.00 0.98 0.96 0.99 1.01 1.02 1.01
ECHO-T2DM 0.89 0.80 0.90 0.91 0.87 0.64 0.64
UKPDS OM 0.98 0.92
UKPDS RE 0.91
CDC-RTI 0.96 0.88 0.93 0.80 0.74 0.83
CARDIFF 0.91 1.03 0.97
EBMI 0.93 0.99
Note. Relative risk represents the ratio of event risk in the intervention group versus the control group. ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation trial, a 5-year trial in type 2 diabetes in which patients were randomly assigned to undergo either standard glucose control or intensive glucose control, defined as
the use of gliclazide plus other drugs as required to achieve an Hb A1c value of 6.5% or less; CARDIFF, Cardiff Research Consortium Model; CDC-RTI, the Centers for Disease Control and
Prevention-RTI Diabetes Cost-effectiveness Model; CVD, cardiovascular disease; EBMI, the Evidence-Based Medicine Integrator Simulator; ECHO-T2DM, The Swedish Institute of Health
Economics model titled Economics and Health Outcomes in Type 2 Diabetes Mellitus Model; IMS CORE, IMS CORE Diabetes Model; MI, myocardial infarction; MICHIGAN, the Michigan Model for
Diabetes; UKPDS OM, the United Kingdom Prospective Diabetes Study Outcomes Model; UKPDS RE, the United Kingdom Prospective Diabetes Study Risk Engine.
* Combined fatal and nonfatal MI and stroke.
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Table 4 – Summary of validation results for a glucose-lowering intervention in the ADVANCE trial (secondary end points).
Model Death
from any
cause
All
CVD
events
All
coronary
events
Major
coronary
events
All
cerebrovascular
events
Major
cerebrovascular
events
Heart
failure
PVD New-
onset
MA
New/
worsening
neuropathy
ADVANCE
Intensive 22.1% 8.9% 10.1% 5.6% 6.3% 4.3% 3.9% 6.2% 23.7% 42.4%
Standard 22.4% 9.6% 10.3% 6.1% 5.9% 4.4% 4.1% 6.6% 25.7% 41.5%
IMS CORE
Intensive 14.9% 13.1% 12.4% 8.7% 2.9% 2.9% 3.3% 1.9% 5.4% 12.6%
Standard 15.9% 13.4% 13.2% 9.4% 3.1% 3.1% 3.4% 2.5% 6.6% 15.4%
MICHIGAN
Intensive 10.3% 15.9% 22.2%
Standard 10.1% 16.7% 22.2%
ECHO-T2DM
Intensive 19.4% 16.3% 11.3% 3.6% 2.7% 10.1% 1.4%
Standard 21.5% 17.3% 12.6% 4.2% 3.0% 10.1% 2.0%
UKPDS 17.3% 7.2% 3.3% 2.9%
OM 17.8% 7.7% 3.7% 3.2%
Intensive
Standard
CDC-RTI
Intensive 16.4%
Standard 16.7%
CARDIFF
Intensive 1.0%
Standard 1.2%
EBMI
Intensive 27.7% 24.4% 4.8% 8.8% 9.1% 2.7% 8.6% 9.4%
Standard 28.7% 25.2% 5.6% 8.8% 9.2% 2.7% 9.6% 9.7%
ADVANCE Relative risk 0.99 0.93 0.98 0.92 1.07 0.98 0.95 0.94 0.92 1.02
IMS CORE Relative risk 0.94 0.98 0.94 0.93 0.93 0.93 0.95 0.75 0.81 0.82
MICHIGAN 1.02 0.95 1.00
ECHO-T2DM 0.90 0.94 0.89 0.86 0.91 1.00 0.68
UKPDS OM 0.97 0.93 0.90 0.90
CDC-RTI 0.98
CARDIFF 0.89
EBMI 0.96 0.97 0.86 1.00 0.99 0.98 0.90 0.97
Notes. The UKPDS Risk Engine did not report appropriate outcomes for the secondary end point analysis of the ADVANCE trial. Relative risk represents the ratio of event risk in the intervention
group versus the control group. ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial, a 5-year trial in type 2 diabetes in
which patients were randomly assigned to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide plus other drugs as required to achieve an Hb
A1c value of 6.5% or less; CARDIFF, Cardiff Research Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-RTI Diabetes Cost-effectiveness Model; CVD, cardiovascular
disease; EBMI, the Evidence-Based Medicine Integrator Simulator; ECHO-T2DM, The Swedish Institute of Health Economics model titled Economics and Health Outcomes in Type 2 Diabetes
Mellitus Model; IMS CORE, IMS CORE Diabetes Model; MA, microalbuminuria; MICHIGAN, the Michigan Model for Diabetes; PVD, peripheral vascular disease; UKPDS OM, the United Kingdom
Prospective Diabetes Study Outcomes Model.
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Fig. 2 – Summary of model validation results for the ADVANCE trial (primary end point). ADVANCE, Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial, a 5-year trial in type 2 diabetes in
which patients were randomly assigned to undergo either standard glucose control or intensive glucose control, defined as
the use of gliclazide plus other drugs as required to achieve an Hb A1c value of 6.5% or less; CARDIFF, Cardiff Research
Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-RTI Diabetes Cost-effectiveness Model; CVD,
cardiovascular disease; EBMI, the Evidence-Based Medicine Integrator Simulator; ECHO-T2DM, The Swedish Institute of
Health Economics model titled Economics and Health Outcomes in Type 2 Diabetes Mellitus Model; IMS CORE, IMS CORE
Diabetes Model; MI, myocardial infarction; MICHIGAN, the Michigan Model for Diabetes; UKPDS OM, the United Kingdom
Prospective Diabetes Study Outcomes Model; UKPDS RE, the United Kingdom Prospective Diabetes Study Risk Engine.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 7 0 – 6 8 5 679of the ACCORD trial. The models tended to overestimate the
incidence of cardiovascular mortality in the ACCORD population,
the exceptions being the IMS CORE Diabetes Model and the
Cardiff Model, which reported values closest to those observed
in the trial. However, all models failed to predict the increased
risk of cardiovascular mortality associated with the intensive
intervention in the ACCORD trial. Modeled estimates of all-cause
mortality were generally higher than those reported in the
ACCORD trial. The exception here was the Cardiff Model, which
reported all-cause mortality incidences close to those in the
ACCORD trial. Only the Cardiff Model and the EBMI Simulator
predicted an increased risk of all-cause mortality with intensive
therapy in the ACCORD population, although the relative risks
reported were not a close match for the value from the ACCORD
data set.Discussion
The general consensus on the results presented at the Fifth
Mount Hood Challenge was that, in general, the models per-
formed reasonably well in terms of predicting the relative risk of
interventions versus control treatments, but less well in terms of
the estimation of absolute risk. While relative effects are impor-
tant to many decision makers, predictions of absolute effects
may be needed, not just the relative changes if absolute amounts
of money spent or saved need to be predicted, or how many
adverse clinical events will be prevented or caused. Absolute
rates of events may also be important to people designing clinical
trials, as they directly affect the power of the trial and therefore
the sample size, duration, and cost. When discussing thedifficulty of simulating the trials, it is important to distinguish
between simulating the outcomes in the control group versus the
outcomes in the intervention group. For some of the trials (e.g.,
ACCORD glucose lowering) modeling the effect of the interven-
tion was challenging, whereas the outcome rates in the control
groups can still provide very useful tests of the models’ accu-
racies in addressing risk factors and the progression of compli-
cations with current care. The selection of trials for the validation
exercise at the Fifth Mount Hood Challenge was deliberately
challenging. For example, the ASPEN study was specifically
chosen because it produced a different result (i.e., no statistically
significant benefit of atorvastatin treatment on the primary
composite end point) from Collaborative Atorvastatin Diabetes
Study (CARDS), which was used in a previous Mount Hood
Challenge in 2004. The ADVANCE study reported data from a
fairly atypical type 2 diabetes population: patients were generally
old, with long-standing advanced diabetes but not on insulin,
and with over one-third of the population recruited to study
centers in Asia. Historically, there has been a paucity of data
available to inform the modeling of ‘‘high-risk’’ populations such
as those in ADVANCE and ACCORD. Moreover, the relative lack of
data on the cardiovascular risk profile in Asian patients with type
2 diabetes (relative to their Western counterparts) has made
accurate modeling of outcomes challenging in the ADVANCE
population. Data from the ACCORD trial has challenged previ-
ously accepted wisdom on the role of aggressive treatment of risk
factors in diabetes. Aggressive treatment of blood pressure did
not lead to a statistically significant composite outcome of fatal
and nonfatal major cardiovascular events in the ACCORD trial,
and intensive therapy targeting Hb A1c value below 6% was
shown to increase mortality without significantly reducing major
Fig. 3 – Summary of model validation results for the ADVANCE trial (secondary end points). The UKPDS Risk Engine did not
report appropriate outcomes for the secondary end point analysis of the ADVANCE trial. ADVANCE, Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial, a 5-year trial in type 2 diabetes in
which patients were randomly assigned to undergo either standard glucose control or intensive glucose control, defined as
the use of gliclazide plus other drugs as required to achieve an Hb A1c value of 6.5% or less; CARDIFF, Cardiff Research
Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-RTI Diabetes Cost-effectiveness Model; CVD,
cardiovascular disease; EBMI, the Evidence-Based Medicine Integrator Simulator; ECHO-T2DM, The Swedish Institute of
Health Economics model titled Economics and Health Outcomes in Type 2 Diabetes Mellitus Model ; IMS CORE, IMS CORE
Diabetes Model; MA, microalbuminuria; MICHIGAN, the Michigan Model for Diabetes; PVD, peripheral vascular disease;
UKPDS OM, the United Kingdom Prospective Diabetes Study Outcomes Model.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 7 0 – 6 8 5680cardiovascular events. Because many of the models rely primarily
on data linking risk factors to hard end points from landmark
studies that predate these more recent and perhaps atypical data
sets, the validation exercise set for the Fifth Mount Hood
Challenge was a very demanding one. Many of the models were
not able to reproduce all the primary outcomes and many of the
secondary outcomes of each of the trials.
During the meeting discussion session, the modeling groups
raised a number of issues that may have contributed to the
discrepancies in absolute risk between the model predictions
and the trial results. Matching population characteristics were
cited by several groups as a testing aspect of the validation
analyses (due to complicated inclusion and exclusion criteria in
the trials). Difficulties around effectively modeling risk for a
patient with a history of complications (adjusting for the risk of
second events) and covariance (e.g., patient age with duration of
diabetes and/or history of complications, or ethnicity with baseline
blood pressure) were also cited as major challenges, particularly
when modeling without patient-level data. Different interpreta-
tions of end points were widely acknowledged as a reason that the
model results did not match trial results in several cases. (For
example, very few of the models captured revascularization as an
end point, and differing methods were used to define and measure
the occurrence of retinopathy end points.) These difficulties can be
compounded when local treatment practice influences the end
point. (For example, the clinical decision on when to perform
revascularization can vary widely between regions and countries.)
Another limitation of most models highlighted during the
discussion was their failure to report fatal and nonfatal events
separately (even though this is an integral part of the modelingcalculations going on in the background). This would seem to be
an essential function of a model, and future improvements will
need to address these shortcomings. Differing assumptions
around the progression of risk factors over time in the modeling
analyses were also raised as a barrier to matching the trial
results. (For example, Hb A1c, SBP, or serum lipid level changes
over time.) It was also clear that different modelers had used
different assumptions about other risk factors and this may have
been a source of discrepancy in the results presented. As part of
this discussion, the paucity of data on risk factor progression in
type 2 diabetes was acknowledged. At present the only published
formulae for risk factor progression are those from the UKPDS
[14]. Although some modern trials have reported data on Hb A1c
progression (e.g., Fenofibrate Intervention and Event Lowering in
Diabetes study provides data on Hb A1c progression on modern
therapy over 5 years), more work is needed in this area.
Methodological issues were also discussed at the Fifth Mount
Hood Challenge, arising from the challenge simulations. In light
of the data from the ACCORD trial, the following question was
raised: What should the relationship between Hb A1c levels and
mortality be in diabetes models? Although some trial results
suggest that the relationship could be U-shaped, more evidence
is clearly needed to provide a definitive answer. This is an
epidemiological puzzle that may become clearer in the years
ahead. Another issue raised concerned the modeling of risk via
changing risk factors as opposed to the direct treatment effects
on end points (e.g., the gliclazide stroke effect). Most models
currently rely on physiological risk factors (and patient
characteristics) to estimate the risk of events. Although it
would be advantageous to include specific treatment effects
Table 5 – Summary of validation results for a blood pressure–lowering intervention in the ACCORD trial.
Model Primary
end
point
Death
from any
cause
CVD
mortality
Fatal
stroke
Major
coronary
disease
event
Nonfatal
MI
Any
stroke
Fatal or
nonfatal
HF
ACCORD
Intervention 1.9% 1.3% 0.5% 2.3% 1.1% 0.3% 0.7%
Control 2.1% 1.2% 0.5% 2.4% 1.3% 0.5% 0.8%
IMS CORE
Intervention 1.0% 2.6% 0.4% 0.02% 0.9% 0.4% 0.2% 0.5%
Control 1.2% 2.7% 0.4% 0.03% 0.9% 0.5% 0.3% 0.6%
MICHIGAN
Intervention 2.3% 1.7% 0.9% 0.2% 2.0% 1.0% 0.7%
Control 2.8% 1.7% 1.0% 0.2% 2.4% 1.3% 0.9%
ECHO-T2DM
Intervention 2.2% 2.0% 0.9% 0.1% 2.0% 1.0% 0.4% 0.6%
Control 2.6% 2.0% 1.0% 0.2% 2.3% 1.1% 0.6% 0.7%
UKPDS OM
Intervention 1.7% 2.7% 1.0% 1.8% 0.4% 0.6%
Control 1.9% 2.7% 1.0% 2.0% 0.5% 0.7%
UKPDS RE
Intervention 1.9%
Control 2.1%
CDC-RTI
Intervention 1.7% 2.9% 1.5% 0.4% 0.3%
Control 1.9% 2.9% 1.6% 0.4% 0.4%
CARDIFF
Intervention 1.0% 1.2% 0.4% 0.0% 0.4% 0.3% 0.2%
Control 1.1% 1.1% 0.4% 0.1% 0.4% 0.4% 0.2%
EBMI
Intervention 5.09% 2.52% 0.36% 2.43%
Control 5.15% 2.51% 0.61% 2.38%
ACCORD Relative risk 0.88 1.07 1.06 0.94 0.87 0.59 0.94
IMS CORE Relative risk 0.85 0.98 0.91 0.69 0.90 0.90 0.69 0.91
MICHIGAN 0.84 0.96 0.91 0.85 0.86 0.80 0.82
ECHO-T2DM 0.85 0.98 0.90 0.85 0.87 0.86 0.69 0.85
UKPDS OM 0.88 0.98 1.02 0.92 0.77 0.89
UKPDS RE 0.87
CDC-RTI 0.90 0.99 0.97 0.97 0.85
CARDIFF 0.97 1.00 1.01 0.38 1.04 0.74 1.04
EBMI 0.99 1.00 0.60 1.02
Note. Relative risk represents the ratio of event risk in the intervention group versus the control group. ACCORD, Action to Control Cardiovascular Risk in Diabetes trial, a trial with median 4.7
years of follow-up in participants with type 2 diabetes at high risk for cardiovascular events, randomly assigned to intensive therapy (target SBP o 120 mm Hg) or standard therapy (target
SBPo 140 mm Hg); CARDIFF, Cardiff Research Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-RTI Diabetes Cost-effectiveness Model; CVD, cardiovascular disease;
EBMI, the Evidence-Based Medicine Integrator Simulator; ECHO-T2DM, The Swedish Institute of Health Economics model titled Economics and Health Outcomes in Type 2 Diabetes Mellitus
Model; HF, heart failure; IMS CORE, IMS CORE Diabetes Model; MI, myocardial infarction; MICHIGAN, The Michigan Model for Diabetes; SBP, systolic blood pressure; UKPDS OM, the United
Kingdom Prospective Diabetes Study Outcomes Model; UKPDS RE, the United Kingdom Prospective Diabetes Study Risk Engine.
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Fig. 4 – Summary of model validation results for the ACCORD blood pressure– lowering study. ACCORD, Action to Control
Cardiovascular Risk in Diabetes trial, a trial with median 4.7 years of follow-up in participants with type 2 diabetes at high
risk for cardiovascular events, randomly assigned to intensive therapy (target SBPo120 mm Hg) or standard therapy (target
SBPo140 mm Hg); CARDIFF, Cardiff Research Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-
RTI Diabetes Cost-effectiveness Model; CVD, cardiovascular disease; EBMI, the Evidence-Based Medicine Integrator
Simulator; ECHO-T2DM, The Swedish Institute of Health Economics model titled Economics and Health Outcomes in Type 2
Diabetes Mellitus Model; HF, heart failure; IMS CORE, IMS CORE Diabetes Model; MI, myocardial infarction; MICHIGAN, The
Michigan Model for Diabetes; SBP, systolic blood pressure; UKPDS OM, the United Kingdom Prospective Diabetes Study
Outcomes Model; UKPDS RE, the United Kingdom Prospective Diabetes Study Risk Engine.
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available at the time of launch of new agents (when cost-
effectiveness analyses are required to support reimbursement
decision making).
Differences were acknowledged in the way models generate
simulation cohorts. In some cases, simulation cohorts were
directly generated from distributions based on the available
published trial data. In others, an overall population was gen-
erated and then selected on the basis of clinical trial inclusion/
exclusion criteria to create a simulation cohort. No consensus
was reached on which of these approaches would be best, but it
was agreed that access to patient-level data would improve the
projections made by most of the models presented at the Fifth
Mount Hood Challenge. Although access to patient-level data
from trials is frequently highly restricted, and patient-level
simulation places more demands on computing resources, such
data do allow covariance between different risk factors to be
captured, and this may have important implications for the
accuracy of simulations. To this end, electronic medical registry
data may prove to be a valuable resource for estimating cova-
riance matrices. They may also contain a much more heteroge-
neous set of patients who are more representative of the general
population than are trials with restrictive recruitment criteria.
Such data sets, however, may also have other selection biases
and frequently lack rigorous clinical adjudication of end-point
events in comparison with clinical trials. The only models
presented at the Mount Hood Meeting that captured the influ-
ence of covariance were the UKPDS Outcomes Model and the
ECHO-T2DM Model, both of which use a covariance matrix
developed from patient-level data. The influence of this matrix
on model outcomes has not yet been fully investigated. It may,however, have been one of the reasons why the UKPDS Out-
comes Model and the other models at the meeting that rely on
individual elements of the same UKPDS regression equations to
estimate risk produced different results in the validation
exercises.
The influence of ethnic characteristics on the risk of
complications in patients with type 2 diabetes was also raised
as a point of methodology. While it would be optimal to factor
this fully into the modeling analyses, ethnic group information
is often poorly recorded, confounded with socioeconomic
status, and/or subject to high uncertainty because of small
numbers.
Although the Fifth Mount Hood Challenge Meeting centered
primarily on validation exercises as a vehicle to compare and
contrast modeling methodologies in different groups, it was clear
from the meeting that there is no clear consensus on precisely
what model validation means. Appropriate statistical approaches
should be defined to assess correlation between model and
clinical trial outcomes, and limits could be predefined for model
accuracy and precision. A consensus group with appropriate
statistical expertise may offer the best opportunity to resolve
this long-standing issue.
The Fifth Mount Hood Challenge Meeting included a session
on dealing with statistical uncertainty in simulation models of
type 2 diabetes. Prof. Andrew Briggs highlighted the importance
and many of the challenges in terms of dealing with statistical
uncertainty in complex disease models. The importance of
capturing parameter uncertainty (and dealing with parameter
estimation) was emphasized because it affects decision uncer-
tainty. Structural uncertainty in models, an aspect that is often
overlooked, is being tackled in part by the modeling comparison
Table 6 – Summary of validation results for a glucose-lowering intervention in the ACCORD trial.
Model Duration (y) Primary end
point
All-cause
mortality
CVD
mortality
Nonfatal
MI
Nonfatal
stroke
ACCORD
Intervention 3.5 6.9% 5.0% 1.7% 3.6% 1.3%
Control 7.2% 4.0% 1.3% 4.6% 1.2%
IMS CORE
Intervention 4 10.1% 1.5% 1.9% 0.9%
Control 10.2% 1.9% 2.2% 1.0%
ECHO-T2DM
Intervention 3.5 8.1% 9.4% 3.6% 3.5% 1.3%
Control 9.0% 10.0% 4.1% 3.8% 1.5%
UKPDS OM
Intervention 3.5 6.7% 10.6% 4.6%
Control 7.4% 11.1% 4.7%
UKPDS RE
Intervention 3.5 6.3%
Control 7.1%
CDC-RTI
Intervention 4 11.2% 5.9%
Control 11.3% 6.1%
CARDIFF
Intervention 4 4.8% 1.1% 1.6% 0.8%
Control 4.8% 1.3% 1.7% 0.9%
EBMI
Intervention 3.5 17.3% 3.4% 1.6%
Control 12.4% 4.5% 1.8%
ACCORD Relative risk 3.5 0.96 1.25 1.31 0.78 1.08
IMS CORE 4 0.99 0.79 0.87 0.83
ECHO-T2DM 3.5 0.90 0.94 0.88 0.91 0.88
UKPDS OM 3.5 0.90 0.96 0.97
UKPDS RE 3.5 0.90
CDC-RTI Relative risk 4 0.99 0.97
CARDIFF 4 1.01 0.84 0.96 0.90
EBMI 3.5 1.39 0.74 0.88
Notes. The Michigan Model did not report outcomes for the (optional) glucose- lowering intervention analysis from the ACCORD trial. Relative
risk represents the ratio of event risk in the intervention group versus the control group. ACCORD, Action to Control Cardiovascular Risk in
Diabetes trial, a trial with median 3.5 years of follow-up in participants with type 2 diabetes at high risk for cardiovascular events, randomly
assigned to receive intensive therapy (target Hb A1c value below 6.0%) or standard therapy (targeting Hb A1c value of 7.0%–7.9%); CARDIFF,
Cardiff Research Consortium Model; CDC-RTI, the Centers for Disease Control and Prevention-RTI Diabetes Cost-effectiveness Model; CVD,
cardiovascular disease; EBMI, the Evidence-Based Medicine Integrator Simulator; ECHO-T2DM, The Swedish Institute of Health Economics
model titled Economics and Health Outcomes in Type 2 Diabetes Mellitus Model; Hb A1c, hemoglobin A1c; IMS CORE, IMS CORE Diabetes Model;
MI, myocardial infarction; UKPDS OM, the United Kingdom Prospective Diabetes Study Outcomes Model; UKPDS RE, the United Kingdom
Prospective Diabetes Study Risk Engine.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 7 0 – 6 8 5 683at the Mount Hood meetings. Validation of simulation models
has an important role to play in improving modeling efforts and,
similarly, meetings such as the Mount Hood challenges offer a
unique environment to further this cause. The Fifth Mount Hood
Challenge modelers have performed an additional set of chal-
lenge simulations designed to investigate statistical uncertainty
within the individual models (as well as aspects of structural
uncertainty), and this analysis will be the subject of a future
collaborative article.
Data from the UKPDS have revolutionized the modeling of
type 2 diabetes. Although UKPDS patients continued to be
followed up until 2007, there is clearly a need for additional
patient-level data sets to better understand treatment innova-
tions, novel risk factors, and different target populations. As the
diabetes epidemic continues to grow, particularly in the develop-
ing world, an already complex environment for modelers will
give rise to even more challenges. It could be that the future for
diabetes modeling will rely on the development of country-
specific models or at least country-specific/population-specificrisk estimates. Socioeconomic status and the role of molecular
genetic testing may have an important role to play in future. An
alternative scenario could see collaborative methods, such as
those in the field of climate change, where recommendations are
made on the basis of averages from the results of more than 20
different models [25]. Regardless of these future avenues of
research, meetings such as the Mount Hood challenges will have
an important role to play as modelers seek to continually
improve on the performance of their diabetes models to better
meet the needs of health care decision makers around the world.
Modelers in other disease areas might wish to consider whether
adopting a similar process in their area would have similar
benefits in identifying problems and accelerating improvements.Acknowledgments
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